ORIGINAL ARTICLE |
|
Year : 2018 | Volume
: 66
| Issue : 1 | Page : 55-60 |
|
Topical chemotherapy for giant ocular surface squamous neoplasia of the conjunctiva and cornea: Is surgery necessary?
Sonal S Chaugule1, Jennifer Park2, Paul T Finger1
1 Department of Ocular Tumor and Orbital Disease, The New York Eye Cancer Center; Department of Ophthalmology, The New York Eye and Ear Infirmary of Mt. Sinai, New York, NY, USA 2 Department of Ophthalmology, The New York Eye and Ear Infirmary of Mt. Sinai, New York, NY, USA
Correspondence Address:
Dr. Paul T Finger The New York Eye Cancer Center, Suite 5B, 5th Floor, 115 East 61st Street, New York, NY USA
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/ijo.IJO_590_17
|
|
Purpose: The purpose of this study is to report on the efficacy and safety of topical chemotherapy alone for giant ocular surface squamous neoplasia (OSSN). Methods: In this retrospective, interventional series, 10 eyes with giant OSSN underwent exfoliative biopsy to confirm the diagnosis followed by application of interferon alpha 2b (IFN α2b) and/or 5 fluorouracil, 1% (5FU). Reported outcome measures were tumor response, visual acuity, recurrence, systemic metastasis, and treatment complications. Results: Ten patients (3 female, 7 male) had a mean age of 73 (median, 69; range 40–89) years. Mean tumor diameter was 13.1 (median, 12.3; range 8.2–19.4) mm. Five (50%) eyes were treated with IFN-α2b alone; 1 (10%) with 5-FU alone and 4 (40%) required both IFN-α2b and 5-FU. The mean duration of treatment was 3, 0.5, and 6.4 months for IFN-α2b alone, 5-FU alone, and both IFN-α2b and 5-FU respectively. Complete tumor response was observed in all 10 cases at mean follow-up of 12.8 (median, 11.5; range, 3–25) months. Complications noted were transient irritation and burning (n = 4), dry eyes (n = 2), and transient flu-like symptoms (n = 2). There was no evidence of chemotherapy-related symblepharon, stem cell deficiency, scleral thinning, or corneal opacity. There were no tumor recurrences, and no patient required surgical excision or cryotherapy. Conclusion: Topical chemotherapy was a safe and effective treatment, inducing complete regression in all cases of giant OSSN in this series. There were no sight-limiting complications.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|